{"id":"NCT02334813","sponsor":"University Hospital, Essen","briefTitle":"Daily Prednisone Versus Pulsed Dexamethasone in Treatment-naïve Adult Patients With Immune Thrombocytopenia","officialTitle":"A Randomized Trial of Daily Prednisone Versus Pulsed Dexamethasone in Treatment-naïve Adult Patients With Immune Thrombocytopenia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2002-07","primaryCompletion":"2015-01","completion":"2015-01","firstPosted":"2015-01-08","resultsPosted":"2017-06-09","lastUpdate":"2017-06-09"},"enrollment":26,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Purpura, Thrombocytopenic, Idiopathic"],"interventions":[{"type":"DRUG","name":"Prednisone","otherNames":[]},{"type":"DRUG","name":"Dexamethasone","otherNames":[]}],"arms":[{"label":"Arm A: daily prednisone","type":"ACTIVE_COMPARATOR"},{"label":"Arm B: pulsed dexamethasone","type":"ACTIVE_COMPARATOR"}],"summary":"Patients above age 18 with a first episode of immune thrombocytopenia are randomized 1:1 between 2-4 weeks of daily prednisone (1 mg/kg/d) with subsequent dose tapering (arm A) and six 3-week cycles of pulsed dexamethasone (0.6 mg/kg/d, days 1-4; arm B). The primary endpoint is duration of remission defined as platelets ≥50/nl.","primaryOutcome":{"measure":"Remission Duration","timeFrame":"6 months","effectByArm":[{"arm":"Arm A: Daily Prednisone","deltaMin":3,"sd":null},{"arm":"Arm B: Pulsed Dexamethasone","deltaMin":11,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":2},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":9},"commonTop":["Petechiae","Hypokalemia","Hypertension","Hyperglycemia"]}}